Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer

Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer

Background: Dyspnea is a severe symptom of terminal-stage interstitial pneumonia (IP). We commonly use continuous morphine or midazolam for terminal refractory dyspnea. Objective: We aimed to determine whether there is a difference in the use of continuous morphine and midazolam for terminal dyspnea...

Full description

Bibliographic Details
Main Authors: Hiroko Okabayashi, Hideya Kitamura, Satoshi Ikeda, Akimasa Sekine, Tsuneyuki Oda, Tomohisa Baba, Eri Hagiwara, Takuro Sakagami, Takashi Ogura
Format: Article
Language:English
Published: Mary Ann Liebert 2021-06-01
Series:Palliative Medicine Reports
Subjects:
interstitial pneumonia
lung cancer
midazolam
morphine
palliative care
palliative sedatives
Online Access:https://www.liebertpub.com/doi/full/10.1089/PMR.2021.0010

Internet

https://www.liebertpub.com/doi/full/10.1089/PMR.2021.0010

Similar Items